The emergence of Retatrutide ZPHC, at a concentration of 120mg, is creating considerable buzz within the medical community. This innovative dual GIP and GLP-1 agonist medication suggests to offer notable improvements in body loss compared to previous therapies. Preliminary clinical studies have indicated marked decreases in body mass , potentially